Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: A peritoneal function testing method of using a ratio MTACun/MTACc calculated using MTACun and MTACc as an index for a peritoneal function test. MTACun is an overall mass transfer-area coefficient for urea nitrogen and MTACc is an overall mass transfer-area coefficient for creatinine. Use of the MTACun/MTACc ratio enables examination of the future peritoneal function of a patient (a mechanism of deterioration in peritoneal function). MTACun and MTACc are obtained using a Pyle-Popovich model. The peritoneal function testing method further calculates a permeability coefficient for cell pores (LPSC) and an overall permeability coefficient (LPS) from a Three-Pore Theory model to obtain a ratio LPSC/LPS calculated using the LPSC and the LPS, and further uses the LPSC/LPS ratio and the MTACun/MTACc ratio as indexes for the peritoneal function test.

Abstract: The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination.

Abstract: The present invention relates to high cut-off hemodialysis membranes for the treatment of chronic hemodialysis (CHD) patients, with the potential to improve long-term survival of these patients by reducing the risk of cardiovascular disease, through down-regulation of monocyte activation in the blood. Monocytes are the major circulating blood cells involved in the progression of cardiovascular disease. High cut-off hemodialysis in chronic dialysis patients results in a sustained decrease in expression of monocyte cell-surface proteins that direct the movement of these cells from the blood to the walls of blood vessels, where they promote the progression of arterial disease (atherosclerosis) that leads to cardiovascular disease (CVD); heart disease, strokes and peripheral vascular disease.

Abstract: A method and apparatus for red blood collection and filtration is provided wherein a red blood cell collection assembly provides for leukoreduction filtration concurrent with or soon after the red blood cell separation and collection procedure. Such procedures involve filtering the separated red blood cells in a diluted state after and/or prior to flushing the filter with storage solution. Storage solution may thus be passed through the leukoreduction filter before, with and/or after the RBCs have been filtered therethrough. The red blood cell collection, filtration and storage assembly is preferably preconnected to a blood component separation disposable assembly, including, for example, a centrifuge vessel and a blood removal/return assembly for removing blood from a donor, passing the blood to the centrifuge vessel for separation of the blood into components for collection and providing for filtration of the separated red blood cell component.

Abstract: A system for monitoring water quality for dialysis, dialysis fluids, and body fluids treated by dialysis fluids, is disclosed. The system uses microelectromechanical systems (MEMS) sensors for detecting impurities in input water or dialysis fluid, and in the prepared dialysate. These sensors may also be used to monitor and check the blood of the patient being treated. These sensors include ion-selective sensors, for ions such as ammonium or calcium, and also include amperometric array sensors, suitable for ions from chlorine or chloramines, e.g., chloride. These sensors assist in the monitoring of water supplies from a city water main or well. The sensors may be used in conjunction with systems for preparing dialysate solutions from water for use at home or elsewhere.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: The present invention relates to a device and to a method for determining the dialysis fluid flow rate for an extracorporeal blood treatment device. The dialysis fluid flow rate Qd is determined in accordance with the blood flow rate Qb or the blood flow rate Qb is determined in accordance with the dialysis fluid flow rate Qd, wherein by increasing about a specific value, the increase of a variable characterising the efficiency of the blood treatment, in particular clearance K, does not exceed the specific value. The present invention also relates to a blood treatment device comprising a device for determining the dialysis fluid flow rate or blood flow rate and to a method for operating an extracorporeal blood treatment device. As a result, an optimal dialysis fluid flow rate and/or blood flow rate calculates the requirement in accordance with a high efficiency of the dialysis treatment and in accordance with a reduced consumption of the dialysis liquid.

Abstract: The present invention provides a pharmaceutical composition for dialysis wherein the decline of ionized calcium concentration in an acetate-free bicarbonate dialysate comprising no acetic acid and/or sodium acetate is controlled. The present invention further provides a dialysis agent A that comprises electrolytes, citric acid and/or citrate as pH adjuster, and/or glucose, for preparation of bicarbonate dialysates; the agent A characterized by being adjusted by citric acid and/or citrate so as to keep the electrolyte ionized calcium concentration not less than 1 mmol/L in a prepared bicarbonate dialysate. In a specific aspect of the present invention, sodium citrate is used as citrate, and the present invention provides a dialysate obtained from above.

Abstract: An extracorporeal blood treatment system including: a blood circuit having a first blood passage coupled at a first end to a first end of a blood treatment device and a second blood passage coupled at a first end to a second end of the treatment device, wherein the first and second blood passages each have a second end adapted to be coupled to a vascular system of a human patient; a first blood pump connectable to the first blood passage and a second blood pump connectable to the second blood passage, wherein said first and second blood pumps are adapted to move blood through the first and second blood passages in a first direction and in a reverse direction, and a pump controller operatively connected to the first and second blood pumps, said controller operates the blood pumps to cyclically move blood through the first and second blood passages in the first direction and the reverse direction.

Abstract: The invention relates to control of bubble formation in a fluid during extracorporeal circulation. A fluid supply means (111a) is configured to supply fluid to the extracorporeal circuit (111a, 111b, 113, 114, 115, 116), a flow control means (113) is connectable to the extracorporeal circuit and configured to control the flow of the fluid in the circuit; a gas exchange means (114) is connectable to the circuit and configured to gas exchange of the circulated fluid; an antibubble control unit (125) is connectable to an outlet (123) of the gas exchange means and configured to control the total gas pressure over a gas-exchange membrane (118) of the gas exchange means, whereby the amount of gas in the fluid leaving the gas exchange means can be controlled; and fluid return means (115, 116) is connected to the gas exchange means and configured to reintroduce the fluid into the patient.

Abstract: A treatment assembly is positioned along an AV-fistula and couples therapeutic energy to an adjacent area due to a material response to an applied energy field from a remotely located energy source. The treatment assembly may be delivered into the fistula through a hemodialysis needle, or may be secured to the fistula graft itself and implanted therewith within a patient. A cover provides a shield between an anastomosis area and blood flow. Another AV-fistula includes a valved reservoir that receives a fluid agent from a hemodialysis needle while moving the needle into or from the fistula; the agent leaks from the reservoir into the fistula lumen. Another valved fistula is adjustable between an open condition and closed conditions during and between hemodialysis treatments, respectively. Another AV-fistula has a bladder reservoir coupled to a second refillable fluid reservoir and is adapted to locally deliver a therapeutic agent into the fistula lumen.

Abstract: A hemofiltration system or method removes unwanted molecules from a flow of blood using cascaded first and second hemofilters. Filtration of the blood in first hemofilter raises hemoconcentration of unwanted protein-bound molecules. Combination of a substitution fluid with outflow from the first hemofilter creates a concentration differential between bound and unbound molecules that frees unwanted molecules from protein bonds. Filtration of the combined fluids in a second hemofilter removes the unwanted free molecules. A second substitution fluid may be added to the twice filtered blood fluid for return to a patient. Removal of inflammatory mediators, apoptotic mediators, and certain electrolytes may be effected, and the removal may be optimized by controlling fluid flows and transmembrane pressures.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: An apparatus (100) for extracorporeal blood cleaning includes a separation unit (110), at least two processing branches (120; 130) and a mixing unit (140). The separation unit (110) receives 5 incoming blood (B A) and divides off a first fraction (fC) from this blood. The first fraction (fC) contains predominantly blood cells. The separation unit (110) also divides off at least one second fraction (fP), which contains predominantly blood plasma. A first processing branch (120) processes the first fraction (fC) according to a first cleaning process, in which cell-bound substances are removed from the blood cells. As a result, a first cleaned fraction (fC c) containing washed blood cells is produced. A second processing branch (130) processes the second fraction (fP) according to a second cleaning process in which toxins bound on proteins within the plasma and/or toxins dissolved in 15 the plasma are removed, and a second cleaned fraction (fP c) is produced.

Abstract: The present invention relates to a means of dialysis for removing protein-bound substances from a biological fluid, especially blood or blood plasma, which contains at least one means for solubilizing protein-binding substances to be removed into the biological fluid and/or dialysis fluid, and to a process for removing protein-bound substances from a biological fluid.

Abstract: An air purging method includes: (a) detecting a low fluid level in a blood circuit indicating a high amount of air in the blood circuit; (b) stopping a blood pump; (c) closing a venous patient line; (d) opening a blood circuit air vent valve and a drain valve; and (e) running the blood pump to meter air through the air vent valve and the drain valve to a drain.

Abstract: The present invention generally relates to hemodialysis and similar dialysis systems, including a variety of systems and methods that would make hemodialysis more efficient, easier, and/or more affordable. One aspect of the invention is generally directed to new fluid circuits for fluid flow. In one set of embodiments, a hemodialysis system may include a blood flow path and a dialysate flow path, where the dialysate flow path includes one or more of a balancing circuit, a mixing circuit, and/or a directing circuit. Preparation of dialysate by the preparation circuit, in some instances, may be decoupled from patient dialysis. In some cases, the circuits are defined, at least partially, within one or more cassettes, optionally interconnected with conduits, pumps, or the like. In one embodiment, the fluid circuit and/or the various fluid flow paths may be at least partially isolated, spatially and/or thermally, from electrical components of the hemodialysis system.

Abstract: Solutions, dialysates, and methods for measuring solutes in blood and/or for treating blood. In one aspect of the invention, a method of performing dialysis includes placing a solution in communication with blood of a subject, where a concentration of at least one electrically conductive solute in the solution, prior to being placed in communication with the blood of the subject, is substantially equal to a concentration of the at least one electrically conductive solute in the blood of the subject.

Abstract: The present invention relates to a means of dialysis for removing protein-bound substances from a biological fluid, especially blood or blood plasma, which contains at least one means for solubilizing protein-binding substances to be removed into the biological fluid and/or dialysis fluid, and to a process for removing protein-bound substances from a biological fluid.

Abstract: A blood purification method that purifies blood taken from a body by blood dialysis or by hemodiafiltration includes the step of changing an osmotic pressure of the blood to an increasing condition until a blood volume (BV level) attains a standard blood volume, in a former part of a blood purification process and the step of maintaining a standard blood volume and periodically changing the osmotic pressure of the blood in a later part of the blood purification process.

Abstract: A method and apparatus of priming or rinse back of an extracorporeal circuit using a dialysis machine comprising a dialysis liquid preparation system. The dialysis machine is used to prepare a saline solution on-line. The extracorporeal circuit is connected to the dialysis machine and primed with the saline solution.

Abstract: Therapeutic compositions are provided. The compositions include a single molecule that can display both antioxidant and carbonyl trapping properties. This can effectively reduce inflammation, oxidative stress and carbonyl stress, such as to prevent and/or treat cardiovascular disease and inflammatory diseases in kidney disease patients.

Abstract: A graphical user interface (GUI) for medical instruments for a Renal Replacement Therapy that enables an operator to select and review a series of settings for an extracorporeal pump console and implement the settings in batch manner. The GUI automatically adjusts or recommends dependent settings, e.g. filtration rate, as the user adjusts primary settings, e.g. blood flow rate.

Abstract: A single housing comprising a diluent inlet, a solution outlet, and a plurality of discrete reagent beds comprising at least one reagent in dry form, wherein said reagent is present in the discrete reagent bed in a proportion sufficient for production of a complete hemodialysate solution.

Abstract: Systems and methods relating to dialysis therapy, particularly continuous flow dialysis therapy, are provided. The present invention includes a single closed fluid path along which a minimal amount of therapy fluid including dialysate is fed into, continuously circulated and cleaned such that a therapeutic effective amount of solutes, excess water and the like can be removed from the patient connected to the closed fluid loop during treatment.

Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: A device for carrying fluids for a medical treatment device with two balancing chambers, each having two partial chambers. The filling times of the partial chambers are initially determined using a monitoring device, and then the filling times of the first partial chambers of the first and second balancing chambers, are compared to the filling times of the second partial chambers of the first and second balancing chambers, respectively, to detect leakage or an incomplete filling or discharging of the respective partial chambers.

Abstract: In a blood dialysis system including a source of substitution fluid (10) and a blood dialysis machine, a hemodiafiltration system having a first dialyzer (1) including a first blood compartment (4) having a first blood inlet which receives blood to be cleaned and a first blood outlet which discharges partially diafiltered blood and a first dialysate compartment (5) having a first dialysate inlet and a first dialysate outlet, means (8) for mixing the partially diafiltered blood with substitution fluid from the source to obtain a blood/substitution fluid mixture, and a second hemofilter (2) including a second blood compartment (11) having a second blood inlet which receives the blood/substitution fluid mixture and a second blood outlet which discharges filtered blood and a second permeate compartment (12) having a second permeate outlet.

Abstract: A dual-stage system and methods for using the same include first and second filtration cartridges is provided and is particularly suited for hemodiafiltration and/or hemodialysis. As fluid enters the first filtration cartridge, the hydroxyl ion concentration and hence pH is increased by exposing it to either a strong base or a salt of a weak acid across a filter membrane. This stage allows for improved removal of certain toxins in the fluid, such as protein-bound substances that disassociate more readily from proteins at higher pH. As the filtered fluid enters the second filtration cartridge, the pH of the fluid is restored to normal levels prior to infusion to a patient.

Abstract: A method for preparing a medical liquid from a liquid, such as water, and two concentrated solutions comprises the following steps: circulating the liquid in a conduit (15), at a flowrate Q0; injecting into the conduit (15), at a flowrate Q1, a first concentrated solution containing a first ionic substance A and a second ionic substance B, the ionic substances A and B having, respectively, in the first concentrated solution, a concentration [Asol] and a first concentration [B1sol]; injecting into the conduit (15), at a flowrate Q2, a second concentrated solution containing the first ionic substance A and the second ionic substance B, the first ionic substance A having, in the second concentrated solution, the same concentration [Asol] as in the first concentrated solution, and the second ionic substance B having, in the second concentrated solution, a second concentration [B2sol] different than the first concentration [B1sol] in the first concentrated solution; regulating the injection flowrate Q1 and the

Abstract: A cost effective apparatus for preparing solutions is provided. The apparatus includes a chamber which is divided by a movable partition into two compartments, a dissolving solution supply line for supplying dissolving solution to a first compartment of the chamber, a solution tank, a solution preparing line connecting the solution tank and the first compartment of the chamber, a solution preparing line connecting the solution tank and a second compartment of the chamber, and a transporting pump provided between the solution tank and the second compartment, and a solution transporting line for transporting the solution prepared in the solution tank and that has been transported to the second compartment to the point of use. The transporting pump may alternatively be provided between the first compartment and the solution tank.

Abstract: A method for determining a treatment parameter on a haemofiltration device, as well as a haemofiltration device for applying the method, based on the recognition that a determination method known from haemodialysis can, with little modification, be transferred to haemofiltration. To this effect a physical-chemical characteristic of the substitution fluid and of the fluid which is removed from the haemofilter by way of an ultrafiltrate outlet pipe, is determined. Furthermore, this characteristic is acquired before, after or during a change of this characteristic in the substitution fluid, and is evaluated. As a result, the ion dialysance and thus the urea clearance of a haemofiltration device, which can also be operated as a haemodiafiltration device, can be determined.

Abstract: In contrast to the prior art, the essential components of dialyzing liquids are not provided as a dry concentrate or as a genuine solution at the place of dialysis, but as a suspension of undissolved or incompletely dissolved substances, preferably sodium chloride, optionally sodium acetate, in a solution of the remaining components. The suspension is prepared, stored, transported and used in a form designated as an acid cartridge or acetate cartridge, respectively. At the place of dialysis a liquid dialysis concentrate is prepared from the suspension by means of an apparatus, which is here suggested, and can be processed into dialyzing liquid with the existing dosing and safety systems of commercially available dialyzers. The prestage of a dialysis concentrate, which is described in this invention as a suspension, constitutes the supply form with the highest substance density for the components of acid and acetate-containing dialyzing liquids.

Abstract: The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.

Abstract: The invention relates to a special amino acid mixture for hemodialysis as well as to the dialysis solution that can be prepared from the amino acid mixture. When the amino acid mixtures according to the invention are used for such purposes, the “shrinking men” phenomenon cam be prevented. The present invention also relates to a hemodialysis process and apparatus. This aspect of the invention provides a closed dialysis system with a dialyzer solution containing the amino acid mixtures according to the invention.

Abstract: A dual-stage system and methods for using the same include first and second filtration cartridges is provided and is particularly suited for hemodiafiltration and/or hemodialysis. As fluid enters the first diafiltration cartridge, the hydrogenion concentration (pH) is reduced by exposing it to an acidic solution such as citric acid across a filter membrane. This stage allows for improved removal of certain toxins in the fluid, such as protein-bound substances that disassociate more readily from proteins at lower pH. As the filtered fluid enters the second filtration cartridge, the pH of the fluid is restored to normal levels prior to infusion to a patient.

Abstract: A device for preparing dialysate for a dialysis machine is provided with a cartridge (9) containing salts (S), a first line (6) for supplying purified water to the cartridge (9) to form a saturated solution in the said cartridge (9), a second line (7) for supplying the said saturated solution from the cartridge (9) to the first line (6) and for mixing the saturated solution with the purified water and forming the dialysate, and a discharge line (18) for discharging the said saturated solution from the second line (7) and from the said cartridge (9) at the end of the dialysis treatment.

Abstract: A method for preparing a medical liquid from a liquid, such as water, and two concentrated solutions comprises the following steps:

Abstract: A method for extracorporeal treatment of blood includes preparing a treatment liquid from a liquid and two concentrated solutions by circulating the liquid in a preparation conduit at a flowrate Q0; injecting a first concentrated solution containing at least a first ionic substance A and a second ionic substance B into the preparation conduit at a flowrate Q1; and injecting a second concentrated solution containing at least the first ionic substance A into the preparation conduit at a flowrate Q2. The ionic substance B may have a first concentration in the first concentrated solution and a second concentration, different from the first concentration, in the second concentrated solution. The method may also include regulating the injection flowrates Q1 and Q2 in such a way that at any given time the diluted solution resulting from the mixing of the liquid and the concentrated solutions has a desired concentration of the first ionic substance A and a desired concentration of the second ionic substance B.

Abstract: The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.

Abstract: The invention relates to a special amino acid mixture for hemodialysis as well as to the dialysis solution that can be prepared from the amino acid mixture. When the amino acid mixtures according to the invention are used for such purposes, the “shrinking men” phenomenon can be prevented. The present invention also relates to a hemodialysis process and apparatus. This aspect of the invention provides a closed dialysis system with a dialyzer solution containing the amino acid mixtures according to the invention.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pure hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a matching citrate anticoagulation fluid of a specific composition. The invention also relates to a process for pure hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly further reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration.

Abstract: The present invention relates to a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administed to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. The avoidance of a glucose-like degradation as well as hydrolysis during sterilization and storage while maintaining a neutral mixture pH is achieved according to the invention by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0.

Abstract: The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: An improved method for hemodialysis employing reverse osmosis raises the pH of the blood to preserve the activity of the enzyme lysozyme to improve immune function and reduce the risk of infection in dialysis. In general, this method comprises: (1) removing arterial blood from a patient in need of hemodialysis; (2) increasing the pH of the arterial blood to a value of about 7.8 by adding a sufficient quantity of a 5% solution of sodium chloride buffered to a pH value of 7.9; (3) passing the arterial blood from step (b) through a dialyzer operating by reverse osmosis; (4) adding a pH-reducing agent selected from the group consisting of acetate buffer and dextran sulfate to reduce the pH of the blood to its normal value; (5) passing the blood from step (4) through a dialyzer operating by reverse osmosis to remove antigen; and (6) returning the blood to the patient.

Abstract: A method for measurement of mass and energy transfer parameters (clearance and dialysance) in hemodialysis. A sensor is provided in the dialysate flow path downstream of the dialyzer and means are provided to add concentrate upstream of the dialyzer. A pre-determined amount of a substance whose dialysance is to be measured is added upstream of the dialyzer. The amount of substance riot dialyzed in the dialyzer is measured downstream of the dialyzer by said sensor by integrating the concentration over time. Dialysance is calculated from the amount added upstream, the amount measured downstream and the dialysate flow. In case the substance is part of the dialysate the base concentration is subtracted during integration. The addition of the concentrate upstream of the dialyzer can be done manually or, alternatively by the mixing pump of the dialysis machine. Instead of an increase of the concentration with a concentrate dilution with water can be used as well.